Dermata Therapeutics

- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand -

-The oldest new thing in skincare -

- Dermata expects to launch its first product in the middle of 2026 -

• This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne

• Dermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating its Spongilla technology, in the middle of 2026, first in the U.S.

• Over 3.3 million people are diagnosed with acne in Australia

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants

- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -

- Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 -

- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -

- Dermata expects to launch a new once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit, incorporating its Spongilla technology, in the middle of 2026 -

- Over 3.3 million people are diagnosed with acne in Australia -

- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne -

- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial-

- Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the first half of 2025 -

- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -

- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -

- Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints -

- Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® for the treatment of axillary hyperhidrosis -

- Raised $8.8 million in gross proceeds from private placement and warrant inducement financings during the first quarter of 2025 -

- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -

- Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments -

- XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne -

- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -

- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis - 

- Raised $2.55 million in gross proceeds from a private placement financing in January 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and certain members of the Company's board of directors -

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -

- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -

- The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis -

- This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne -

- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ clinical trial in March 2025 -

- Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy -

- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 -

- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -

- Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment of acne and expects to announce topline results in March 2025 -

- Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy -

- STAR-1 topline results expected in March 2025 -

- Over 30 million acne patients seek treatment in the U.S. each year -

- Phase 2b for DMT310 achieved statistically significant results for all primary endpoints -

- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial -

- Dermata continues discussions with potential botulinum toxin partners for DMT410 -

- Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 -

- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients

- Dermata continues discussions with potential botulinum toxin partners for DMT410

- Raised $2.3 million in net proceeds from financing completed in 2Q 2024

- STAR-1 topline results expected in first quarter of 2025 -

- About 30 million acne patients seek treatment in the U.S. each year -

- DMT310, if approved, could be the first once-weekly topical product for the treatment of acne -